Update shared on06 Oct 2025
Fair value Decreased 4.52%The analyst price target for Amicus Therapeutics was revised downward by $0.73 to $15.36 per share. Analysts cite mixed industry dynamics and recent legal updates influencing valuation assumptions.
Analyst Commentary
Recent analyst reports on Amicus Therapeutics reflect diverging opinions on the company's near-term valuation and long-term prospects. The feedback focuses on the evolving legal landscape, product pipeline, and financial projections.
Bullish Takeaways
- Bullish analysts highlight the company's robust intellectual property position, particularly as key litigation developments progress as anticipated. This supports higher confidence in future revenue streams.
- Several upgrades to Buy or Overweight are attributed to expectations that a favorable resolution of the Galafold case may either result in a beneficial settlement or extend market exclusivity, which could bolster long-term earnings visibility.
- Recent price target increases indicate conviction that the underlying value of Galafold remains solid, even when accounting for the potential launch of generics years into the future.
- Analysts view recent financial misses as primarily due to timing and higher-than-expected rebates rather than underlying demand or execution challenges. This signals maintained growth momentum.
Bearish Takeaways
- Some analysts express caution regarding ongoing legal uncertainties, which could impact near-term share performance or prompt valuation adjustments if outcomes diverge from expectations.
- There are concerns about pricing pressures and elevated rebate rates in key markets that may weigh on margins and necessitate further guidance revisions.
- Market watchers note the importance of patient conversion from competing therapies and emphasize execution risk in achieving expected switch rates for new products.
What's in the News
- Amicus Therapeutics presented new four-year data from the PROPEL open-label extension study, showing sustained muscle function and biomarker improvements in adults with late-onset Pompe disease treated with cipaglucosidase alfa-atga plus miglustat (Key Developments).
- The PROPEL study enrolled 123 adult LOPD patients, with over 95% completing the study. ERT-experienced patients on cipa plus mig walked farther and had improved lung function compared to the comparator group (Key Developments).
- The company reaffirmed its full year 2025 guidance, projecting total revenue growth of 15% to 22% and positive GAAP net income in the second half of 2025 (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has decreased from $16.09 to $15.36 per share, marking a modest downward revision.
- Discount Rate has risen slightly from 6.92% to 7.06%, reflecting increased perceived risk in valuation models.
- Revenue Growth projections have edged down from 20.35% to 20.23%, indicating a marginally more conservative outlook.
- Net Profit Margin expectations have declined from 23.59% to 22.84%, suggesting slightly lower anticipated profitability.
- Future P/E estimate has decreased marginally from 28.31x to 28.11x, which reflects minimal change in forward earnings valuation.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.